About

Specialist in Heart Rhythm Disorders

Dr Han Ling is an Australian-qualified cardiologist, and a specialist in heart rhythm disorders. He has expertise in catheter ablation and devices for cardiac arrhythmias. He is based in Melbourne and practices at the Alfred Hospital, Cabrini Hospital Malvern, and St Vincent's Private Hospital, Fitzroy. Dr Ling is also a medical researcher at the Baker IDI Heart and Diabetes Institute. He holds an academic appointment in the Department of Medicine at the Royal Melbourne Hospital, University of Melbourne.

 

 

Expertise

Catheter ablation for:

  • Atrial fibrillation (AF)

  • Atrial flutter (AFL)

  • Supraventricular tachycardia (SVT)

  • Ventricular tachycardia (VT)

 

Devices for cardiac arrhythmias:

  • Implantable loop recorder implantation (ILR)

  • Permanent pacemaker implantation (PPM)

  • Defibrillator implantation (ICD)

  • Cardiac resynchronization therapy (CRT)

 

 

Experience

Dr Ling completed his medical training at the University of Adelaide in 2002, and was awarded Fellowship of the Royal Australasian College of Physicians as a fully qualified cardiologist in 2010. He specializes in cardiac electrophysiology, and has worked at leading Australian and international centres including the Alfred Hospital, the Royal Melbourne Hospital, and Monash Medical Centre, as well as the renowned Barts Heart Centre (St Bartholomew’s Hospital, UK).

 

 

Research

Dr Ling has a PhD in cardiac electrophysiology awarded by the University of Melbourne. He is well-published in his field, and has won scholarships and awards for his work on AF and heart failure, inlcuding the National Heart Foundation Postdoctoral Fellowship at the Department of Medicine at the Royal Melbourne Hospital, University of Melbourne.

 

 

Awards
  • National Heart Foundation Postdoctoral Fellowship

  • Vincent Fairfax Family Foundation Research Fellowship

  • Australian Government Endeavour Research Fellowship

  • Royal Australasia College of Physicians IMS Overseas Travelling Fellowship

  • Baker IDI Harold Mitchell Travelling Fellowship

  • Pfizer Cardiovascular Lipid Project Grant

  • Pfizer Cardiovascular Lipid Major Travel Grant

  • Cardiac Society of Australia and New Zealand ASM Scholarship

  • National Heart Foundation Postgraduate Research Scholarship

  • Cardiac Society of Australia and New Zealand Postgraduate Research Scholarship

  • Baker IDI Bright Sparks Scholarship

 

 

Memberships and Associations
  • Royal Australasian College of Physicians (RACP)

  • National Heart Foundation (NHF)

  • Cardiac Society of Australia and New Zealand (CSANZ)

  • Heart Rhythm Society (HRS)

  • European Society of Cardiology (ESC)

  • Alumni of the University of Melbourne

  • Alumni of the University of Adelaide

 

 

Presentations
  • Ventricular arrhythmias in heart failure. Invited speaker, Advanced Heart Failure Symposium (Melbourne) 2015.

  • Sinus rhythm and quality of life in the age of modern therapies for AF: Results form the PREFER in AF registry. Oral abstract, European Cardiac Arrhythmia Society (Paris) 2015.

  • Sociodemographic and cardiovascular status but not anticoagulant choice independently predict quality of life in patients with atrial fibrillation: results from the PREFER in AF registry. Oral abstract, Heart Rhythm Congress, UK (Birmingham) 2014.

  • Atrial Fibrillation Ablation in Patients with Cardiomyopathy and No Delayed Enhancement On Cardiac Magnetic Resonance Imaging: Sinus Rhythm Restores Ventricular Function. Oral abstract, Heart Rhythm Society (Denver) 2013.

  • Magnetic resonance imaging identifies persistent left ventricular dilatation and diffuse fibrosis long after functional recovery in tachycardia-mediated cardiomyopathy: a 5-year follow up study. Oral abstract, Asia-Pacific Heart Rhythm Society (Taipei) 2012.

  • Diffuse ventricular fibrosis in atrial fibrillation is associated with aging, ejection fraction, and body mass index. Oral abstract, CSANZ (Brisbane) 2012.

  • Magnetic resonance imaging identifies persistent left ventricular dilatation and diffuse fibrosis long after functional recovery in tachycardia-mediated cardiomyopathy: a 5-year follow up study. Oral abstract, CSANZ (Brisbane) 2012.

  • Validation of contrast-enhanced magnetic resonance T1 mapping of the human atrium: Quantification of remodelling associated with atrial fibrillation. Oral abstract, CSANZ (Brisbane) 2012.

  • Diffuse ventricular fibrosis in atrial fibrillation is associated with aging, ejection fraction, and body mass index. Oral abstract, Heart Rhythm Society (Boston) 2012.

  • Atrial fibrillation: Treatment options. Plenary lecture, Australasian Cardiovascular Nursing College (Melbourne) 2011.

  • Impact of catheter ablation for atrial fibrillation among patients with left ventricular systolic dysfunction. Oral abstract, NHF (Melbourne) 2011.

  • Impact of atrial fibrillation on ventricular calcium handling and contractile function. Oral abstract, CSANZ (Adelaide) 2010.

  • Impact of atrial fibrillation on ventricular calcium handling and contractile function. Oral abstract, Pfizer CVS Forum (Melbourne) 2010.

  • Predicting maintenance dose in patients on perhexiline: beyond genotype. Oral abstract, CSANZ (Adelaide) 2008.

  • Understanding thrombogenic risk in atrial fibrillation. Invited speaker, SA Cardiology Registrars’ State Meeting (Adelaide) 2007.

  • Poisoning with the recreational drug paramethoxyamphetamine. Invited speaker, AMSS (Melbourne) 2001.